t(KMT2A;v)
About
Gene context: KMT2A
Biomarker Type: Rearrangement
Present: True
Rearrangement Type: Translocation
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | t(KMT2A;v) | Acute Lymphoid Leukemia | Revumenib | |
| FDA (1) | t(KMT2A;v) | Acute Myeloid Leukemia | Revumenib | |
| FDA (1) | t(KMT2A;v) | Burkitt Lymphoma | Revumenib | |
| FDA (1) | t(KMT2A;v) | Acute Leukemias of Ambiguous Lineage | Revumenib |